Corcept Therapeutics is upgraded to Buy after a patent loss and FDA setback, with focus shifting to relacorilant in oncology.

Through year-end 2025, McIntyre Partnerships' results were approximately 8% gross and 6% net. At month-end, our exposures are ...

NVIDIA Corporation projects 67% revenue growth and 30% upside as AI accelerator demand and FCF generation accelerate. Check ...

Gran Tierra Energy said it sold its remaining stake in the Simonette asset in Alberta for C$62.5M, and announced a new ...

The Southern Company faces a 21x P/E valuation and execution risks from a $76B CapEx plan with a $72 fair value estimate.

BrainStorm Cell Therapeutics (BCLI) secures a $1M private placement at a premium, funding NurOwn ALS Phase 3b and regulatory ...

FDA approves AbbVie’s VENCLEXTA + acalabrutinib for first-line CLL, the first all-oral fixed-duration option—see AMPLIFY data ...

Boot Barn delivered strong 3Q26 results with 16% revenue growth, positive comps, and robust EPS expansion. Check out why BOOT ...

Grail (GRAL) shares plunge after NHS-Galleri results missed primary endpoint but showed fewer Stage IV cases in 12 deadly ...

Figma, Inc. has a $13B market cap and 82% gross margins with a 136% net dollar retention rate and 30% growth guidance. Find ...

TTM Technologies is an AI and defense PCB supplier with 57% data center growth and a $1.61B backlog. Click here to read an ...

Walmart Q4 2026 beats show automation gains, but FY2027 outlook lags vs. a ~50x P/E valuation. Click here to read an analysis ...